85. Idiopathic interstitial pneumonia Clinical trials / Disease details
Clinical trials : 627 / Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05255991 (ClinicalTrials.gov) | October 4, 2022 | 15/2/2022 | Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-2) | Idiopathic Pulmonary Fibrosis;Interstitial Lung Disease | Drug: Placebo;Drug: Inhaled Treprostinil;Device: Treprostinil Ultrasonic Nebulizer | United Therapeutics | NULL | Recruiting | 40 Years | N/A | All | 396 | Phase 3 | Argentina;Australia;Chile;Denmark;France;Israel;Korea, Republic of;Mexico;Spain;Taiwan |
| 2 | EUCTR2021-005881-17-DK (EUCTR) | 12/09/2022 | 15/07/2022 | A study evaluating the efficacy and safety of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (TETON-2) | Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: TYVASO® (treprostinil) inhalation solution, for oral inhalation use Product Name: Treprostinil INN or Proposed INN: Treprostinil | UNITED THERAPEUTICS CORPORATION | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 396 | Phase 3 | Taiwan;Spain;Chile;Israel;United Kingdom;Italy;France;Mexico;Argentina;Belgium;Denmark;Australia;Peru;Germany;Netherlands;New Zealand;Korea, Republic of | ||
| 3 | NCT04905693 (ClinicalTrials.gov) | September 6, 2022 | 20/5/2021 | Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis;Interstitial Lung Disease | Drug: Inhaled Treprostinil;Device: Treprostinil Ultrasonic Nebulizer | United Therapeutics | NULL | Enrolling by invitation | 40 Years | N/A | All | 792 | Phase 3 | United States |
| 4 | NCT04708782 (ClinicalTrials.gov) | June 1, 2021 | 12/1/2021 | Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis;Interstitial Lung Disease | Drug: Placebo;Drug: Inhaled Treprostinil;Device: Treprostinil Ultrasonic Nebulizer | United Therapeutics | NULL | Recruiting | 40 Years | N/A | All | 396 | Phase 3 | United States |
| 5 | NCT00705133 (ClinicalTrials.gov) | July 2008 | 23/6/2008 | Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension | Using Either Intravenous (IV) or Subcutaneous (SQ) Treprostinil to Treat Pulmonary Hypertension Related to Underlying Interstitial Lung Disease | Pulmonary Arterial Hypertension;Interstitial Lung Disease;Idiopathic Pulmonary Fibrosis | Drug: Treprostinil | Rajan Saggar | United Therapeutics | Completed | N/A | N/A | All | 15 | Phase 2 | United States |
| 6 | NCT00703339 (ClinicalTrials.gov) | June 2008 | 19/6/2008 | Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis | A Single-Dose, Dose-Escalating Study Exploring the Safety, Pharmacokinetics, and Pharmacodynamic Effects of Inhaled Treprostinil Sodium Using the Nebu-Tec OPTINEB Inhalation Device in Patients With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis;Pulmonary Hypertension | Drug: Treprostinil sodium for inhalation | Lung Biotechnology PBC | NULL | Terminated | 35 Years | 80 Years | All | 1 | Phase 2 | United States |